Dr. Ott on the CheckMate-032 Study in Gastric and GEJ Cancer

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction cancer.

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction (GEJ) cancer.

In this trial, 59 patients with either gastric or GEJ cancer were treated with nivolumab (Opdivo), most of which had received 2 or more prior lines of therapy.

The overall survival was promising, says Ott, with durable responses observed.

Related Content:

ESMO World Congress on Gastrointestinal CancerOncLive TVGastrointestinal Cancer
TARE Gains Traction as Suitable Alternative to TACE for Locoregional HCC Therapy
Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer